PURPOSE: Pembrolizumab is a humanized monoclonal antibody that blocks interaction between programmed death receptor-1 (PD-1) and its ligands (PD-L1, PD-L2). Although pembrolizumab is approved for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), its role in the management of locally advanced (LA) disease is not defined. We report a phase IB study evaluating the safety and efficacy of adding pembrolizumab to cisplatin-based chemoradiotherapy in patients with LA HNSCC. PATIENTS AND METHODS: Eligible patients included those with oral cavity (excluding lip), oropharyngeal, hypopharyngeal, or laryngeal stage III to IVB HNSCC (according to American Joint Committee on Cancer, 7th edition, staging system) eligible for cisplatin-based, standard-dose (70 Gy) chemoradiotherapy. Pembrolizumab was administered concurrently with and after chemoradiotherapy with weekly cisplatin. Safety was the primary end point and was determined by incidence of chemoradiotherapy adverse events (AEs) and immune-related AEs (irAEs). Efficacy was defined as complete response (CR) rate on end-of-treatment (EOT) imaging or with pathologic confirmation at 100 days postradiotherapy completion. Key secondary end points included overall (OS) and progression-free survival (PFS). RESULTS: The study accrued 59 patients (human papillomavirus [HPV] positive, n = 34; HPV negative, n = 25) from November 2015 to October 2018. Five patients (8.8%) required discontinuation of pembrolizumab because of irAEs, all of which occurred during concurrent chemoradiotherapy; 98.3% of patients completed the full planned treatment dose (70 Gy) of radiotherapy without any delays ≥ 5 days; 88.1% of patients completed the goal cisplatin dose of ≥ 200 mg/m2. EOT CR rates were 85.3% and 78.3% for those with HPV-positive and -negative HNSCC, respectively. CONCLUSION: Pembrolizumab in combination with weekly cisplatin-based chemoradiotherapy is safe and does not impair delivery of curative radiotherapy or chemotherapy in HNSCC. Early efficacy data support further investigation of this approach.
PURPOSE:Pembrolizumab is a humanized monoclonal antibody that blocks interaction between programmed death receptor-1 (PD-1) and its ligands (PD-L1, PD-L2). Although pembrolizumab is approved for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), its role in the management of locally advanced (LA) disease is not defined. We report a phase IB study evaluating the safety and efficacy of adding pembrolizumab to cisplatin-based chemoradiotherapy in patients with LA HNSCC. PATIENTS AND METHODS: Eligible patients included those with oral cavity (excluding lip), oropharyngeal, hypopharyngeal, or laryngeal stage III to IVB HNSCC (according to American Joint Committee on Cancer, 7th edition, staging system) eligible for cisplatin-based, standard-dose (70 Gy) chemoradiotherapy. Pembrolizumab was administered concurrently with and after chemoradiotherapy with weekly cisplatin. Safety was the primary end point and was determined by incidence of chemoradiotherapy adverse events (AEs) and immune-related AEs (irAEs). Efficacy was defined as complete response (CR) rate on end-of-treatment (EOT) imaging or with pathologic confirmation at 100 days postradiotherapy completion. Key secondary end points included overall (OS) and progression-free survival (PFS). RESULTS: The study accrued 59 patients (human papillomavirus [HPV] positive, n = 34; HPV negative, n = 25) from November 2015 to October 2018. Five patients (8.8%) required discontinuation of pembrolizumab because of irAEs, all of which occurred during concurrent chemoradiotherapy; 98.3% of patients completed the full planned treatment dose (70 Gy) of radiotherapy without any delays ≥ 5 days; 88.1% of patients completed the goal cisplatin dose of ≥ 200 mg/m2. EOT CR rates were 85.3% and 78.3% for those with HPV-positive and -negative HNSCC, respectively. CONCLUSION:Pembrolizumab in combination with weekly cisplatin-based chemoradiotherapy is safe and does not impair delivery of curative radiotherapy or chemotherapy in HNSCC. Early efficacy data support further investigation of this approach.
Authors: Arlene A Forastiere; Helmuth Goepfert; Moshe Maor; Thomas F Pajak; Randal Weber; William Morrison; Bonnie Glisson; Andy Trotti; John A Ridge; Clifford Chao; Glen Peters; Ding-Jen Lee; Andrea Leaf; John Ensley; Jay Cooper Journal: N Engl J Med Date: 2003-11-27 Impact factor: 91.245
Authors: K Kian Ang; Qiang Zhang; David I Rosenthal; Phuc Felix Nguyen-Tan; Eric J Sherman; Randal S Weber; James M Galvin; James A Bonner; Jonathan Harris; Adel K El-Naggar; Maura L Gillison; Richard C Jordan; Andre A Konski; Wade L Thorstad; Andy Trotti; Jonathan J Beitler; Adam S Garden; William J Spanos; Sue S Yom; Rita S Axelrod Journal: J Clin Oncol Date: 2014-09-20 Impact factor: 44.544
Authors: Petr Szturz; Kristien Wouters; Naomi Kiyota; Makoto Tahara; Kumar Prabhash; Vanita Noronha; Ana Castro; Lisa Licitra; David Adelstein; Jan B Vermorken Journal: Oncologist Date: 2017-05-22
Authors: Joshua Bauml; Tanguy Y Seiwert; David G Pfister; Francis Worden; Stephen V Liu; Jill Gilbert; Nabil F Saba; Jared Weiss; Lori Wirth; Ammar Sukari; Hyunseok Kang; Michael K Gibson; Erminia Massarelli; Steven Powell; Amy Meister; Xinxin Shu; Jonathan D Cheng; Robert Haddad Journal: J Clin Oncol Date: 2017-03-22 Impact factor: 44.544
Authors: Vasavi Paidpally; Abdel K Tahari; Stella Lam; Krishna Alluri; Shanthi Marur; Wayne Koch; Richard L Wahl; Rathan M Subramaniam Journal: J Nucl Med Date: 2013-10-07 Impact factor: 10.057
Authors: David J Adelstein; Yi Li; George L Adams; Henry Wagner; Julie A Kish; John F Ensley; David E Schuller; Arlene A Forastiere Journal: J Clin Oncol Date: 2003-01-01 Impact factor: 44.544
Authors: S Andrew Skillington; Dorina Kallogjeri; James S Lewis; Jay F Piccirillo Journal: JAMA Otolaryngol Head Neck Surg Date: 2016-06-01 Impact factor: 6.223
Authors: Antoniu-Oreste Gostian; Rainer Fietkau; Markus Hecht; Markus Eckstein; Sandra Rutzner; Jens von der Grün; Thomas Illmer; Gunther Klautke; Simon Laban; Matthias G Hautmann; Thomas B Brunner; Bálint Tamaskovics; Axel Hinke; Jian-Guo Zhou; Benjamin Frey; Anna-Jasmina Donaubauer; Ina Becker; Sabine Semrau; Arndt Hartmann; Panagiotis Balermpas; Wilfried Budach; Udo S Gaipl; Heinrich Iro Journal: J Immunother Cancer Date: 2022-01 Impact factor: 13.751
Authors: Barbara Seliger; Chiara Massa; Bo Yang; Daniel Bethmann; Matthias Kappler; Alexander Walter Eckert; Claudia Wickenhauser Journal: Int J Mol Sci Date: 2020-09-24 Impact factor: 5.923
Authors: Markus Hecht; Antoniu Oreste Gostian; Markus Eckstein; Sandra Rutzner; Jens von der Grün; Thomas Illmer; Matthias G Hautmann; Gunther Klautke; Simon Laban; Thomas Brunner; Axel Hinke; Ina Becker; Benjamin Frey; Sabine Semrau; Carol I Geppert; Arndt Hartmann; Panagiotis Balermpas; Wilfried Budach; Udo S Gaipl; Heinrich Iro; Rainer Fietkau Journal: J Immunother Cancer Date: 2020-10 Impact factor: 13.751